Company / R&D Expense
SAB Biotherapeutics, Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$30.3M
FY2025
5-year range
$16.5M / $57.2M
FY2021-FY2025
Trend
+83.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $30M.
Based on SEC 10-K filings.
$30M in FY2025 with a 3-year CAGR of -19.1%.
Declined from $36M to $30M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -19.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -19.1%, indicating a declining trend.
- In FY2025, r&d expense increased 83.2% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.3M | +83.2% |
| FY2024 | $16.5M | -54.7% |
| FY2023 | $36.4M | -36.3% |
| FY2022 | $57.2M | +104.9% |
| FY2021 | $27.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026